Share:
MPR news story
Topline data were announced from a head-to-head phase 4 trial (COMPARE study) comparing the reactogenicity profiles of Nuvaxovid (COVID-19 Vaccine, Adjuvanted) with mNEXSPIKE (COVID-19 Vaccine, mRNA) following vaccination.
Nuvaxovid exhibited a more favorable reactogenicity profile compared with mNEXSPIKE.
Read the full news story here.
Source : MPR
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.